Up 13% in a month, Polynovo share price bounces back after being dumped from ASX 200

What’s going on with the Polynovo share price?

| More on:
Two happy scientists analysing test results.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Polynovo share price has surged nearly 13% in a month 
  • In the past year, the company's share price has rocketed 50% 
  • Managers have been buying up Polynovo shares, potentially a sign of management confidence 

The Polynovo Ltd (ASX: PNV) share price has jumped ahead in the past month despite losing its place on the ASX 200.

The company’s share price has jumped nearly 13% from $1.185 at market close on 3 June to the current price of $1.335. In contrast, the S&P/ASX 200 Index (ASX: XJO) has lost nearly 9% in the same time frame.

So why has the Polynovo share price had such a good month?

Why has the Polynovo share price risen?

Polynovo is an ASX healthcare share working on medical devices, using patented technology Novosorb.

Polynovo shares have jumped amid insider trading among the company’s management.

The company’s chair David Williams bought $284,142 worth of shares on 6 June and 7 June alone. In total, he purchased 250,000 shares in these two days.

Williams has purchased more than $5 million worth of shares since the start of May, as my Foolish colleague Aaron reported.

Insider buying can be a sign that management is optimistic about the future direction of a company.

Polynovo reported record revenue of $12.6 million in the March quarter, up 59% compared to the same time in the previous year. The company’s ANZ sales picked up substantially in the quarter, up 81.9% compared to the same time last year.

In recent news, Polynovo has completed settlement on the sale of its headquarters in Port Melbourne.

The company’s headquarters sold for $6.35 million.

In recent times, Polynovo shares have made the list of the 10 most shorted ASX shares. However, as my Foolish colleague James reported, short interest in the company has eased to 7.9%.

Polynovo share price snapshot

The Polynovo share price has descended 50% in the past 12 months, while it is down 12% in the year to date.

In comparison, the benchmark ASX 200 has lost nearly 10% over the past year.

Polynovo has a market capitalisation of nearly $884 million based on today’s share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

Medibank share price dips despite dividend boost

The healthcare insurer will pay its biggest final dividend since 2019.

Read more »

Three medical staffers sit at a table and chat happily wearing hospital scrubs
Earnings Results

Pro Medicus share price fails to fly on 44% profit leap

Here's how Pro Medicus dialled up the profits in FY22.

Read more »

A CSL scientist looking through a telescope in a lab
Earnings Results

Telix share price slides despite 726% revenue boost

Investors may be thinking the pharmaceutical company's valuation has peaked after the stock price doubled over the past three months.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Broker Notes

Broker gives its verdict on the CSL share price post-FY22 results

Here's what this broker is saying about the CSL share price...

Read more »

An older woman tries to listen by cupping her ear.
Healthcare Shares

Guess which ASX biotech share is soaring 32% on a ‘landmark’ FDA ruling

What a day it has become for this small-cap healthcare company.

Read more »

Two happy scientists analysing test results.
Dividend Investing

Everything you need to know about the latest CSL dividend

Own CSL shares? Here's the details regarding its latest dividend.

Read more »

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
Healthcare Shares

CSL share price drops despite expectations of growth in FY23

Investors are punishing CSL. What's going on?

Read more »

ventilator mask
Healthcare Shares

Why ‘the outlook is very bullish’ for the Resmed share price: Tribeca

ResMed has been rated as a buy by Tribeca.

Read more »